An approved LGSOC drug funds the runway while a KRAS G12D inhibitor races three simultaneous registration trials — proof of efficacy in Phase 2 is the make-or-break condition

Verastem is a commercial-stage oncology company with an approved targeted cancer drug for a rare ovarian cancer and a second targeted cancer drug not yet approved for pancreatic, lung, and colorectal cancers.

Verastem holds a rare dual-track position: AVMAPKI FAKZYNJA is commercially approved for KRAS-mutated recurrent low-grade serous ovarian cancer and generating revenue, while VS-7375, an oral KRAS G12D inhibitor, has just enrolled first patients across three registration-directed Phase 2 trials in pancreatic, lung, and colorectal cancers. The thesis resolves on whether VS-7375 Phase 2 data demonstrate registrational-quality efficacy sufficient for accelerated approval across at least one indication. The primary risk is that the single-arm accelerated approval pathway faces inherent regulatory uncertainty, and next-generation KRAS inhibitors from better-capitalized programs could establish a higher efficacy bar before VS-7375 data mature.